Arrowhead Pharmaceuticals, Inc. (ARWR) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $89.41. The rating moved from Neutral to Overbought on August 5, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$89.41
• Last changeMoved from Neutral to Overbought on August 5, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Arrowhead Pharmaceuticals, Inc. (ARWR) is centered on an RNAi therapeutic platform with multiple development programs and potential near‑term catalysts. The macro and market environment described is steady, which supports orderly trading, but the company remains exposed to binary clinical and financing events that will drive short‑term moves. Positive outcomes or partnership/M&A activity could materially improve upside, while trial setbacks, cash‑need dilution, or manufacturing issues represent the primary headwinds. Absent new filings or announced readouts in the provided window, the outlook is balanced with moderate volatility expected around upcoming milestones.

Key factors

• Proprietary RNAi therapeutic platform with the potential for differentiated mechanisms of action across multiple indications
• Pipeline progress and the prospect of near-term clinical readouts that could materially re-rate shares
• Favorable biotech M&A backdrop and deal multiples that can create strategic optionality for mid-stage developers
• Moderate investor interest in growth/biotech names amid steady overall market tone, supporting liquidity for share moves on catalysts
• Operational leverage to positive trial outcomes given the binary nature of clinical milestones

Risks

• Binary clinical trial outcomes and regulatory setbacks that can produce sharp share price declines
• Capital runway and potential dilution risk if additional financing is needed ahead of value‑creating milestones
• Competition from other RNAi, gene‑editing, biologic and oligonucleotide developers targeting similar disease pathways
• Manufacturing, CMC, or supply‑chain challenges that delay development or commercialization
• Payer, pricing and reimbursement pressure that could limit commercial upside even after successful trials
• General biotech sector volatility and rotation away from growth names that can amplify downside risk

Latest MarketMoodz coverage

• Morgan Stanley Upgrades ARWR to Overweight; PT $100 Ahead of Phase 32026-04-21

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.